CTSO

Zacks Small Cap Research – CTSO: CytoSorbents Announces Submission of DrugSorb-ATR Application to the FDA – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT DrugSorb-ATR Submission On October 1, 2024, CytoSorbents (NASDAQ:CTSO) announced the submission of its DrugSorb-ATR medical device De Novo marketing application to the U.S. Food and Drug Administration (FDA) on September 27, 2024. The goal of this product is to reduce the severity of perioperative … Read more

Zacks Small Cap Analysis – CTSO: CytoSorbents Potential for Excessive Margin Income Progress Helps Worth Goal of $4.00 – Go Well being Professional

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 2nd quarter 2024 outcomes on August thirteenth and the outcomes have been principally above our expectations. For the 2nd quarter of 2024, complete revenues elevated roughly 5.0% to $9.9 million. Complete product gross sales have been $8.8 million, a rise of … Read more

x